Researchers identified fecal S100 calcium-binding protein B (S100B) as a potential biomarker for assessing severity in patients with Clostridioides difficile infection. The study reported a diagnostic correlation between fecal S100B levels and disease severity, aiming to support earlier risk stratification in clinical settings. The development matters because C. difficile management often relies on clinical trajectories and standard markers that may not capture severity early enough to guide escalation decisions. A measurable stool-based signal could help clinicians triage patients and adjust intensity of treatment sooner. For biotech and diagnostics, the key implication is demand for noninvasive, fast severity tools in infectious disease—especially as clinicians manage antimicrobial resistance and resource constraints. If validated in larger cohorts, fecal S100B could become an inexpensive add-on for severity assessment pathways.